JPM vs SBET
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
JPM exhibits a concerning Piotroski F-Score of 2/9, indicating weak short-term fundamental health, and currently trades at a significant premium to both its Graham Number ($239.11) and Intrinsic Value ($140.07). While the company maintains a strong ROE of 16.13% and dominant market positioning, negative YoY earnings growth (-3.60%) and bearish insider activity from the CEO and CFO signal internal caution. The stock's current price of $313.68 suggests the market is pricing in a growth premium that is not currently supported by the deterministic health or value metrics.
SBET exhibits critical financial instability, highlighted by a Piotroski F-Score of 1/9, indicating severe fundamental weakness. While the company shows explosive year-over-year revenue growth of 1816%, this has not translated into profitability, as evidenced by a catastrophic operating margin of -4657.07% and consistent, massive earnings misses. The extreme disconnect between the 'Strong Buy' analyst consensus and the actual financial health suggests a speculative bubble or misplaced optimism. With a 5-year price decline of 99.1% and bearish insider activity, the company appears to be in a high-risk state of distress.
Compare Another Pair
Related Comparisons
JPM vs SBET: Head-to-Head Comparison
This page compares JPMorgan Chase & Co. (JPM) and Sharplink, Inc. (SBET) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.